Committed to innovation and growth

Karl Mahler Head of Investor Relations

Bill Anderson Head of Global Product Strategy

June 2013 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website – www.roche.com 2 All mentioned trademarks are legally protected Update on 2013

Strategy, R&D productivity and allocation of resources

Growth platforms and product highlights

Summary Q1 2013: Strong start to the year

2013 2012 Change in % CHF bn CHF bn CHF CER

Pharmaceuticals Division 9.2 8.6 6 7

Diagnostics Division 2.4 2.4 1 1

Roche Group 11.6 11.0 5 6

4 CER=Constant Exchange Rates Q1’ 13: US and Emerging markets driving sales growth

Pharma Diagnostics

Asia- Asia 10% 10% Pacific

Latin Latin 7% America 4% America

EEMEA 11%

North US 13% America -4%

Japan 2% Japan -2%

Europe 1% EMEA 1%

All growth rates at CER=Constant Exchange Rates; EEMEA=Eastern Europe, Middle East, Africa; 5 EMEA=Europe, Middle East and Africa Continued high sales growth1

8% 6% 6% 6% 6% 4% 4% 4% 2% 2% 1% 0% 0% 0% -2%

-4% -3% -5% -6% Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1' '10 '10 '11 '11 '11 '11 '12 '12 '12 '12 13

6 At CER=Constant Exchange Rates Update on 2013

Strategy, R&D productivity and allocation of resources

Growth platforms and product highlights

Summary Roche strategy: Focused on medically differentiated therapies

Regulators: Pharma Dia Optimised benefit / risk ratio Payors: Focus Optimised benefit / cost ratio

MedTech

Premium Premium for innovation OTC Generics

Differentiation

8 Personalised Healthcare - benefit for all stake holders, including the industry

Today Benefit from patient stratification Future

Increased market share Reduced Pricing Patient pool power

Time to market

Lower development costs Higher probability of success

9 R&D productivity differs substantially among players

Average annual 1 NME peak sales (2001-10) $ 710 m Peak Sales 4 x US$ bn (per $1 bn R&D)

Roche

$ 165 m Peak Sales (per $1 bn R&D)

Average annual R&D investment (1997-2006)1 US$ bn

1 Peak sales and R&D calculated pro forma to account for major M&A 10 Source: EvaluatePharma; BCG analysis; Roche analysis Roche: R&D well balanced from a risk & disease point of view

2012 Roche budget

Oncology

Metabolism Inflammation

CNS Virology

0% 5% 10% 15% 20% 25% 30%

Industry average probability of success – Phase 0 to Registration

11 Source: Bernstein Equity Research, Tufts University and Roche analysis R&D spend: Balance between short and long term

R&D spend by phase ~50% ~50%

Invest for Invest for the the future near term

Research/ Phase 0 Phase 1 Phase 2 Phase 3 Filing Phase 4 Discovery

12 Note: Based on 2012 budget Implications of R&D productivity challenge Segregation will continue as only true innovation

will be rewarded

High high

differentiation

True innovators

‘Me-too’ players ??

Generics Medicaldifferentiation No / limited

differentiation low

low Willingness to pay for added value high 13 Update on 2013

Strategy, R&D productivity and allocation of resources

Growth platforms and product highlights

Summary Roche Oncology A portfolio of distinctive drugs

(CHF mn) 25'000.00

20'000.00

15'000.00

10'000.00

5'000.00

'0.00 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

CER - @ A12 CHF*

15 Note: Sales at 2011 FX rates Roche oncology: one approval in 1 tumor type to 9 medicines in 14 tumor types

Kadcyla HER 2+ BC Perjeta HER 2-positive BC Erivedge Basal Cell Carcinoma Zelboraf Pancreatic cancer Tarceva Lung cancer Ovarian Renal cancer Recurrent glioblastoma Metastatic breast cancer Avastin Lung cancer Metastatic colorectal cancer Gastric cancer Xeloda Colon cancer Colorectal cancer Breast cancer HER2-positive gastric cancer Herceptin Early HER2-positive breast cancer HER2-positive metastatic breast cancer CLL MabTheraRituxan Agressive NHL Indolent NHL 1997 2005 2013 Improving cancer treatment with combinations 29 internal combinations with 18 compounds in over 9 tumor types, and increasing…

Solid tumors Hematological tumors Breast cancer Colon cancer Lymphoma Perjeta Herceptin  Avastin Ph2 Anti-CD22 ADC Rituxan Ph2 Perjeta Herceptin  Anti-EGFL7 Avastin Ph2 Anti-CD79b ADC Rituxan Ph2 Kadcyla Perjeta Ph3 Anti-PDL1 Avastin Ph1 Bcl2 inh Rituxan (+B) Ph1 Kadcyla Perjeta Ph3 Perjeta Herceptin Ph3 Melanoma Leukemia Onartuzumab Avastin Ph2 Zelboraf Ph3 Bcl2 inh GA101 Ph1 Pictilisib (PI3Ki) Kadcyla Ph1 Anti-PDL1 Zelboraf Ph1 Bcl2 inh Rituxan Ph1 Pictilisib (PI3Ki) Herceptin Ph1 Bcl2 inh Rituxan (+B) Ph1 Lung cancer Gastric, brain, kidney and others Onartuzumab Tarceva Ph3 Perjeta Herceptin Ph3 Onartuzumab Avastin Ph2 Onartuzumab Avastin Ph2 Anti-EGFL7 Avastin Ph2 Anti-PDL1 Avastin Ph1 Pictilisib (PI3Ki) Avastin Ph2 Cobimetinib AKT inh Ph1 Pictilisib (PI3Ki) Avastin Ph1 Cobimetinib Pictilisib (PI3Ki) Ph1 Pictilisib (PI3Ki) Tarceva Ph1 Anti-HER3 MAb Tarceva Ph1

17  Studies read out/filed/approved Avastin sales: Back to solid growth

CHF m 1,800 11% YoY CER growth 11% 8% 1% 5% -6% -9% -10% -2%

1,200

,600 International Japan Europe US ,0 Q1 '11 Q2 '11 Q3 '11 Q4 '11 Q1 '12 Q2 '12 Q3 '12 Q4 '12 Q1 '13

18 Absolute amounts at 2012 exchange rates Cervical cancer: 3rd most common cancer in women worldwide

Patient population Unmet medical need

GOG 240 • Very few treatment advances, 40,000 ~11’900 chemo radiation established as Recurrent patients Stage IVb standard of care in 1999 with Stage I-IVa ~80% platinum based therapies 30,000 • Patient population that generally lacks access to good health care

GOG 240 GOG 240 • Lack of HPV vaccination and lack 20,000 ~ 4’500 ~ 4’000 patients of screening patients • Highest incidence in Latin 10,000 America and East Europe/Middle East/Africa regions

,0 EU4 US Brazil 19 Strategies beyond great medicines

HER2 franchise Replace and extend

Extend Perjeta Replace

Perjeta

Kadcyla Kadcyla

Herceptin Herceptin + chemo + chemo

Medical value Medical + chemo

EMILIA / MARIANNE CLEOPATRA MARIANNE

20 Changing the standard of care in HER2 Securing future growth by improving the standard of care

Biosimilars launch (EU)

2nd line Xeloda + lapatinib T-DM1 (EMILIA) mBC

Herceptin Herceptin & Perjeta + 1st line T-DM1 & Perjeta (MARIANNE) mBC + chemo chemo (CLEOPATRA)

Adjuvant Herceptin Herceptin subcutaneous + chemo Herceptin & Perjeta T-DM1 & Perjeta BC + chemo (HannaH) + chemo (APHINITY) + chemo

2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Filing timelines

Established standard of care Potential new standard of care Potential future standard of care

21 HER2-positive early breast cancer Perjeta and Kadcyla aim to improve cure rates

Perjeta in neo-adjuvant setting Kadcyla in adjuvant setting

45.8% 14 cycles pCR S Herceptin U Residual HER2+ eBC response, response, R invasive Preoperative 29.0% tumor, pCR chemotherapy G (breast or 24.0% + Herceptin E nodes) complete R Kadcyla 16.8% Y

Pathological

Herceptin + Herceptin & Herceptin & Perjeta + docetaxel Perjeta + Perjeta docetaxel • First patient in: April 2013 docetaxel • FDA granted a SPA (Special Protocol Assesment) NEOSPHERE trial • 1 of 3 planned Kadcyla trials in early to be filed in US in Q2 2013 breast cancer 22 1Declaration that an uncompleted Phase III trial's design, clinical endpoints, and statistical analyses are acceptable for FDA approval HER2 franchise sales expected to grow further

CHF bn 1.8

15% YoY CER growth 1.6 14% 16% 10% 7% Kadcyla 1.4 Perjeta Herceptin 1.2

1 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013

23 Strategies beyond great medicines

Hematology Replace and extend

BCL2 Extend ADCs Replace BCL2 ADC 22 ADCs ADC 79b

GA101 GA101 ADC 22 Chemo ADC 79b

Medical value Medical

MabThera MabThera

CLL11 etc. Romulus Our vision

24 Changing the standard of care in hematology Different mechanisms of action

Filed in Q2 2013 and received breakthrough designation by FDA 2012 2014 2016 2018 2020

MabThera Rituxan*

GA 101

Bcl-2

Anti-CD22 ADC or Anti-CD79b ADC

25 * Patent expiry in the US: 2018 GA101 in CLL: Investigator-assessed PFS (months)

Stage Ia Stage Ib 1.0 1.0

G-Clb: R-Clb:

0.9 Median 23.0 mo* 0.9 Median 15.7 mo 1-year PFS 84% 0.8 0.8 1-year PFS 63% 0.7 0.7

0.6 0.6 free survival

- 0.5 0.5 Clb: Clb: 0.4 Median 10.9 mo 0.4 Median 10.8 mo 1-year PFS 27% 1-year PFS 27% 0.3 0.3

0.2 0.2 Stratified HR: 0.14 Stratified HR: 0.32

Progression 0.1 95% CI: 0.09–0.21 0.1 95% CI: 0.24–0.44 p < 0.0001 (log-rank) p < 0.0001 (log-rank) 0.0 0.0 0 3 6 9 12 15 18 21 24 27 0 3 6 9 12 15 18 21 24 27 n at risk Clb 118 99 82 47 18 5 3 0 0 0 Clb 118 101 85 49 19 6 3 0 0 0 G-Clb 238 213 207 152 117 75 40 15 2 0 R - Clb 233 225 215 148 95 63 28 11 3 0

• Type 1 error controlled through closed test procedure; p-value of the global test was <.0001. • * In the G-Clb arm < 10% of patients had reached the median at cutoff; therefore, in contrast to the Clb arm • the G-Clb median PFS could not be reliably estimated due to the few patients at risk at time of G-Clb median. • Independent Review Committee (IRC) - assessed PFS was consistent with investigator-assessed PFS 26 CI = confidence interval; HR = hazard ratio. Tumor PD-L1 enables cancer immune evasion Anti-PDL1 inhibits binding of PD-L1 to PD-1 and B7.1

Targeting PDL1 Targeting PD-1

27 Selecting the patients most likely to benefit Companion diagnostics

Anti-PDL1 immunohistochemistry Companion diagnostics factors

(proprietary /Roche PD-L1 IHC) • Highly sensitive and specific anti-PDL1 antibody used for IHC • PD-L1 expression on tumor cells • PD-L1 expression on PD-L1 tumor infiltrating immune cells • Appropriate diagnostic cut-off • Prospective evaluation of diagnostic T cell cancer cell

28 Anti-PDL1: Disease control rate Phase I

Overall disease control rate Disease control rate by tumor type

100 Disease Control Rate (ORR1 + SD) All comers1 Dx-positive2 80

Overall Phase I 61% 86% experience (86/140) (31/36) 60 50 Metastatic 54% 100% NSCLC (22/41) (5/5) 40 41 Patients,% Metastatic 58% 87% 28 Melanoma (22/38) (13/15) 20 33 72% 80% 20 Metastatic RCC 13 (34/47) (8/10) 0 PD-L1 positive PD-L1 negative All comers

Best response: Complete response Partial response Stable disease 29 1 All patients include PD-L1-positive, PD-L1-negative and patients with unknown tumor PD-L1 status; 2 Diagnostic positivity based on Roche PD-L1 IHC Anti-PDL1: Salvage of BRAF-mutant metastatic melanoma patient after progression on Zelboraf

Baseline Week 6 Week 12 Week 18

31% increase in Post-Resection target lesions (RECIST PD)

Dx: Nov 2010 (cutaneous melanoma) Prior treatment: cisplatin, . Week 46

Images include data from after Feb 1, 2013 Dana Farber Cancer Institute (Ibrahim/Hodi). 30 Q1 2013: Pharma sales Tamiflu, Oncology and Actemra main growth drivers

Tamiflu +84%

Avastin +11%

Herceptin +11%

MabThera/Rituxan +6%

Actemra/RoActemra +32%

Perjeta NA

Evista -100% US Pegasys -15% Europe Japan Boniva/Bonviva-59% International

-,100 -,50 ,0 ,50 ,100 ,150 ,200

31 31 Absolute amounts in CHF m at Constant Exchange Rates (CER) average 2012; all growth rates at CER Lucentis: signs of stabilisation supported by continued growth in DME

Lucentis quarterly sales (USD m) AMD 500 • 0.5 mg less frequent than monthly dosing regimen added to label February 2013 400 Eylea • Competitive environment remains wAMD challenging

Lucentis RVO 300 DME • Lucentis share stable DME

200 • Further increase in patient share Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 '10 '10 '10 '10 '11 '11 '11 '11 '12 '12 '12 '12 '13

32 AMD=wet age-related macular degeneration; RVO=retinal vein occlusion; DME=diabetic macular edema Actemra: Superiority in monotherapy (ADACTA) drives market share growth

Biologic therapy today Actemra market share (patient shares)1 in monotherapy segment2 30% 25%

30% 20%

70% 10%

Biologic monotherapy 0% Biologic combination Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 '09 '09 '10 '10 '11 '11 '12 '12

• 1st line biologic use approved in US October 2012 • Subcutaneous formulation filed in US and EU December 2012 33 1Data from biologics registries and US claims database; 2Market share for DE, FR, IT, ESP, UK, predefined target groups

Emerging markets remain strong

1,200 Q1 ‘13 1H ‘12 2H ‘12 +11% +13% +15% 1,000 -27% 0% +9% ,800 +18% India Russia +7% S. Korea ,600 Turkey +5% Mexico

,400 Brazil China

,200 +20%

,0 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013

34 All growth YoY at CER=Constant Exchange Rates Increasing polarisation in emerging markets Growth in patented medicines and unbranded generics

Example: Brazil market showing evidence of polarisation

100% 90% Non-categorised 80% Protected originals 70% Share expected 60% to grow further Unbranded copies 50% 40% Branded copies 30% 20% Non-patented originals 10% 0% 2000 2005 2010 35 Source: IMS Update on 2013

Strategy, R&D productivity and allocation of resources

Growth platforms and product highlights

Summary Q1 2013: Pipeline milestones

aleglitazar metabolic diseases lebrikizumab mGluR2 antagonist asthma treatment-resistant depression gantenerumab1 mGluR5 antagonist Alzheimer’s treatment-resistant depression ocrelizumab crenezumab MS Alzheimer's bitopertin Anti-PD-L1* HCV combo schizophrenia solid tumours HepC MEKi Anti-EGFL7 etrolizumab melanoma solid tumours ulcerative colitis Oncology onartuzumab (MetMAb) EGFR ADCC MAb (GA201) Anti-factor D Neuroscience NSCLC solid tumours geographic atrophy Virology (GA101) * PI3 kinase Anti-PCSK9 Immunology CLL solid tumours metabolic diseases Ophthalmology Kadcyla dual PI3 kinase/mTOR inclacumab (P selectin)* HER2+ BC solid tumours ACS/CVD Metabolism Ph III NMEs Late stage enabling data expected in 2013

2013 R&D to remain stable *Data presentation planned/presented 37 1Phase II/III label enabling Roche: Operating profit and margin continuously increased

Group core operating profit and margin 37.7% 34.9% 35.6% % of sales 33.0% 33.2% +11%1

17.16 16.27 16.59 15.07 15.15

CHF bn

2008 2009 2010 2011 2012 38 1 At CER=Constant Exchange Rates Roche: Cash flow and margin continuously increased

Group operating free cash flow and margin

% of sales 33.8% 32.1% 32.3% 29.8% 27.1% +10%1

15.7 15.4 14.1 13.7 12.4

CHF bn

2008 2009 2010 2011 2012 39 1 At CER=Constant Exchange Rates Summary: Focus on innovation and growth

Strategic focus on innovation and driving Personalised 1 Healthcare

Strong growth in US and Emerging Markets; 2 innovative access models

3 Leading product pipeline providing value for the future

40 Doing now what patients need next Anti-PDL1: Phase I data in solid tumors

Efficacy Response rates1 All comers2 Dx-positive3 Overall Phase I 21% 36% experience (29/140) (13/36) 22% 80% Metastatic NSCLC (9/41) (4/5) 29% 27% Metastatic Melanoma (11/38) (4/15) 13% 20% Metastatic RCC (6/47) (2/10) 26 of 29 responders continued to respond at last assessment (time on study of 3 to over 15 months)

Safety Grade 3/4 • No grade 3-5 pneumonitis observed adverse events % (n) • Immune-related Grade 3-4 AEs observed in 4 patients (2%) All Grade 3/4 Events 43% (73/171) Hyperglycemia 5% (9/171) • Treatment-related Grade 3-4 AEs in 22 patients (13%) Fatigue 4% (7/171) Increased ALT 3% (5/171) Dyspnea 3% (5/171) Hypoxia 3% (5/171) 42 1 Efficacy evaluable subjects first dosed at 1-20 mg/kg prior to Aug 1, 2012; data cutoff Feb 1, 2013; ORR includes unconfirmed PR/CR and confirmed PR/CR by RECIST 1.1 2 All patients include PD-L1-positive, PD-L1-negative and patients with unknown tumor PD-L1 status; 3 Diagnostic positivity based on Roche PD-L1 IHC GA101 in NHL: Phase III development

GADOLIN study Induction Maintenance CR, PR, GA101 SD GA101 + bendamustine Primary end-point: PFS -refractory q2mo x 2 years Expect data: 2015 iNHL x 6 cycles (n=360) Bendamustine x 6 cycles

GOYA study GA101 x 8 cycles + Previously untreated CHOP x 6 or 8 Primary end-point: PFS DLBCL Expect data: 2015 (n=1,400) MabThera x 8 cycles + CHOP x 6 or 8

Induction Maintenance GALLIUM study GA101 x 8 cycles + CHOP x 6 or GA101 GA101 x 8 cycles + CVP x 8 or q2mo x 2 years GA101 x 6 cycles + benda. x 6 First-line iNHL Primary end-point: PFS CR, PR (n=1,400) Expect data: 2017 MabThera x 8 cycles + CHOP x 6 or MabThera MabThera x 8 cycles + CVP x 8 or q2mo x 2 years MabThera x 6 cycles + benda. x 6 43 NME submissions and their additional indications Projects currently in phase 2 and 3

obinutuzumab (GA101) etrolizumab (RG7413) FrontlineDLBCL NHL ulcerative colitis

obinutuzumab (GA101) quilizumab (RG7449) Frontline NHL asthma

onartuzumab (MetMAb) lebrikizumab (RG3637) gastric cancer & other AIs asthma

imgatuzumab EGFR (RG7160) RG7667 bitopertin (RG1678) solid tumors CMV obsessive compulsive dis. pictilisib mericitabine (RG7128) gantenerumab (RG1450) PI3 kin inh (RG7321) HCV Alzheimer‘s solid tumors

obinutuzumab (GA101) PI3K/mTOR inh (RG7422) danoprevir (RG7227) MAO-B inh (RG1577) iNHL relapsed solid & hem tumors HCV Alzheimer‘s setrobuvir (RG7790 ) mGluR2 antag (RG1578) aleglitazar EGFL7 MAb (RG7414) HCV depression type-2 diabetes (US/China) solid tumors CD22 ADC (RG7593) aleglitazar (RG1439) mGluR5 (RG7090) onartuzumab (MetMAb) aleglitazar (RG1439) CD79b ADC (RG7596 nd rd CV risk red CVD in T2D/pre-T2D depression mNSCLC, 2 /3 line CV risk red post ACS in T2D heme tumors

cobimetinib (MEK inh) bitopertin (RG1678) HER3/EGFR (RG7597) inclacumab (RG1512) crenezumab (RG7412) (RG7421) combo Zelboraf schizophrenia# m. epithelial tumors ACS/CVD Alzheimer‘s met melanoma lampalizumab obinutuzumab (GA101) octreolin (RG3806) ocrelizumab (RG1594) glypican-3 MAb (RG7686) PCSK9 MAb (RG7652) anti-factor D Fab (RG7417) CLL acromegaly PPMS and RMS liver cancer metabolic diseases geographic atrophy 2013 2014 2015 2016 and beyond

Unless stated otherwise, submissions are planned to occur in US and EU. Oncology Neuroscience  indicates a submission which has occurred with regulatory action pending Immunology Ophthalmology # negative symptoms and sub-optimal control Virology NME CardioMetabolism 44 Status as of March 31, 2013